Summary of Study ST000530
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000389. The data can be accessed directly via it's Project DOI: 10.21228/M8S02S This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST000530 |
| Study Title | Effects of herb DG and KK01 on Type 2 Diabetes Mellitus (T2DM) through Lipidomics |
| Study Type | LC-MS lipidomics |
| Study Summary | According to the results in animal test, KK01 is effective in controlling blood glucose increase with comparable effect as metformin and rosiglitazone. This study will conduct lipid profile comparison for serum samples generated from the animal tests. The comparison will be based on the following groups: 1) db/db mice + DG-high dose; 2) db/db mice +DG-low dose; 3) db/db mice + KK01-high dose; 4) db/db mice + KK01-low dose; 5) db/db mice + metformin; 6) db/db mice + rosiglitazone; 7) db/db mice + saline (disease model); and 8) wild type mice + saline (healthy model). The determined lipid marker(s) will be applied to elucidate the drug target(s) and mechanisms of DG and KK01. Furthermore, comparison of target(s) between KK01 and the first line drugs in diabetic treatment, e.g., metformin and rosiglitazone, will facilitate the finding of featured pathway(s) of KK01 differentiated from the established drugs. Comparison of drug target(s) between KK01 and DG can help to understand the synergistic effects of multiple constituents in the herb. |
| Institute | University of North Carolina |
| Department | Systems and Translational Sciences |
| Laboratory | Sumner Lab |
| Last Name | Sumner |
| First Name | Susan |
| Address | Eastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081 |
| susan_sumner@unc.edu | |
| Phone | 704-250-5066 |
| Submit Date | 2016-12-30 |
| Num Groups | 10 |
| Total Subjects | 93 samples for positive mode and 80 samples for negative mode |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2018-02-07 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000566 |
| Treatment Summary: | C57BLKsJ-db/db mice were classified randomly into 8 groups. Seven groups were with 9~10 mice for each and one group with 4 mice. Mice were treated with DG extract (5 g/Kg), DG extract (1 g/Kg), KK01 (50 mg/Kg), KK01 (20 mg/Kg), metformin (5 mg/Kg); rotaglitazone (5 mg/Kg); and saline. Group treated with KK01(20 mg/Kg) and the group with 4 mice treated by saline were used intraperitoneal injection. Other groups were in intragastric administration. Also, a group with ten C57BLKsJ mice fedding with saline was used as healthy control. The drug administration were started with the 5th week of the age and lasted for 9 weeks. |
| Treatment Route: | Intragastric administration for all except for group of KK01 low-dose (20 mg/Kg), and 4 db/db mice treated with saline which were treated by intraperitoneal injection. |
| Treatment Dose: | 5 g/Kg for DG high dose; 1 g/Kg for DG low dose; 50 mg/Kg for KK01 high dose; 20 mg/Kg (i.p.) for KK01 low dose; 5 mg/Kg for metformin, 5 mg /Kg for rosiglitazone |
| Treatment Dosevolume: | 0.5 mL |
| Treatment Doseduration: | 9 weeks |
| Treatment Vehicle: | saline |
| Animal Fasting: | Over night |
| Animal Endp Tissue Coll List: | liver, kidney, brain, white fat, brown fat, pancreas |
